Issaquah Brothers Become Brain Surgeons for a Day

By Christina Corrales-Toy

August 28, 2012

Kunal Gupta (left) looks on as his brother Kanav uses a titanium drill on a plastic skull model. Dave Schinkel, a clinical specialist with the drill manufacturer, Medtronic, describes how the drill is handled during surgery. By Greg Farrar

Two Issaquah brothers were among those invited by the Swedish Neuroscience Institute to become brain surgeons for a day on Aug. 24.

The event, hosted by the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment, was held at Swedish’s Cherry Hill campus in Seattle.

The purpose of the event was to give participants a look into the work being done to cure brain cancer and raise awareness of one of the most malignant cancers in the world, which affects more than 22,000 people in the United States.

Kanav and Kunal Gupta had the chance to closely examine a human brain, experiment with surgical devices and learn about brain surgery from Dr. Greg Foltz, a neurosurgeon at the Swedish Neuroscience Institute.

Kanav, a 19-year-old student at the University of Washington, said the event gave him a chance to explore a different medical field.

“I’ve been interested in the medical field for a while and I just want to get an idea of what the specialties are in the field,” he said. “I’ve never really experienced surgery too much in depth, especially related to the brain, so I thought this was an excellent opportunity to get some awareness and exposure to that.”

Kunal, a 15-year-old Issaquah High School student, participated in the event with an eye toward exploring a potential future in medicine.

“I am interested in the medical field and I still don’t know what kind of doctor I want to be,” he said. “So something like this would help me choose what I want my profession to be.”

The day began with a presentation from Foltz, who showed the group a video of a brain surgery he performed just days before.

Next, participants, dressed in scrubs and gloves, had the opportunity to work with instruments like the ones Foltz used in his surgery.

The Gupta brothers eagerly tested every instrument. From using a drill to remove a bone flap from a plastic skull, to dissolving the inner part of an orange with a tool that does the same to tumors, the brothers appreciated working with the high-tech tools and learning the intricacies of brain surgery.

“Being able to see all the various equipment they had was great,” Kanav said. “The biotechnology that goes into making all these different tools and such is quite amazing.”

The best part of the hands-on workshop, the Gupta brothers said, was getting a close view of an actual human brain.

“I really liked looking at the brain,” Kunal said. “It was just a fascinating experience.”

After the hands-on skills session, the participants went on a behind-the-scenes tour of the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment and its research lab. The event ended with a question-and-answer session with a brain cancer survivor and Foltz.

In his presentation, Foltz said brain cancer is highly aggressive and incurable, with a survival rate of only one or two years. He added that, during surgery, he can effectively remove a brain tumor 85 percent of the time. So, one of the keys to curing the disease, he said, is to prevent reoccurrence of the tumor.

The goal of the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment is to provide brain tumor patients with a multidisciplinary team of doctors whose entire focus is to treat both benign and malignant brain tumors.

“We set up this center with the idea that we were going to optimize each patient’s chances of survival,” Foltz said.

Almost 100 people entered for a chance to participate in the event. Due to space limitations, 25 people were randomly chosen to attend. Attendees ranged in age from 15 to 74.


Brain Cancer Patients May Soon Have More Treatment Options Thanks to Ivy Center

Brain Cancer Research in Seattle Leads to New Treatment Options for Patients


By Swedish Neuroscience Institute
Published: Monday, Aug. 27, 2012 – 5:10 am


SEATTLE, Aug. 27, 2012  — Since its opening in 2008, the Ben & Catherine Ivy Center forhas led the expansion drive of major research projects and expanded treatment options for patients living with brain cancer in the Pacific Northwest and throughout the world. The Ivy Center was founded in 2008 to create a world-class treatment and research facility focused on delivering excellent patient care and advancing progress toward more effective treatments for brain cancer.

While great strides have been made in the treatment of breast, colon and other common cancers, only three new drugs to treat brain cancer have been approved by the U.S. Food and Drug Administration in the past 35 years, and these drugs prolong the lives of patients by only a few months. Such a center was needed at the time, said Greg Foltz, M.D., a neurosurgeon and director of the Ivy Center, because brain cancer had been for far too long a neglected or “orphan” disease.

In fact, today the life expectancy of a person diagnosed with glioblastoma, the most common form of malignant primary brain cancer, is only about 15 months — only slightly better than it was a century ago, Dr. Foltz said. “We felt we needed to focus our efforts on coming up with better treatment options,” said Dr. Foltz. “We felt someone had to champion this cause so we embarked on a mission to get more researchers and physicians focused on this disease. And we did.”

Today, the Ivy Center at Swedish has partnered with and led major brain cancer programs with the Ben & Catherine Ivy Foundation, Institute for Systems Biology, Allen Institute for Brain Science, University of Washington, Fred Hutchinson Cancer Research Center, Accium Biosciences and The Elliott Foundation. This has led to a variety of new brain cancer treatment options and research programs for people living with brain cancer in our region. “Previously, none of this existed,” said Dr. Foltz.

Five Years of Progress Made

The goal of the Ivy Center was to create a place where brain tumor patients and their families would have access to the best care and latest clinical research. The Ivy Center has achieved this making it possible for the center’s neurosurgeons, oncologists, radiologists and nursing staff to work in close collaboration with the program’s team of scientists. This collaboration allows clinicians and scientists to provide patients with the best of care as well as direct access to promising new therapies and clinical trials.

The Ivy Center’s clinical team provides comprehensive, integrated care that includes the latest neurosurgery techniques and technology, including intra-operative MRI-guided navigation, precision Gamma Knife radiosurgery as well as the support of a team of physical and occupational therapists, counselors, and other specialists who provide each patient with comprehensive, personalized care.

“People with brain cancer have needs that transcend the traditional requirements of most patients. Care is not just about an operation, it’s not just about a medication,” said Dr. Foltz. “Brain cancer is a life-changing event, so it’s very important from the first meeting that these patients know that we’re there for them, that we care deeply about them and we’re going to provide all the resources that are possible to help them fight their disease.”

Holly Zimmerman, a Bellevue, Wash. resident who has been battling brain cancer and is leading a team in this year’s Seattle Brain Cancer Walk, can speak personally to the importance of the first meeting. “A small seizure led doctors to the discovery of a tumor in my parietal lobe—what immediately followed was brain surgery, radiation, chemotherapy, and a very scary prognosis for me and my family,” said Zimmerman. “This disease is unique and it takes an extraordinary team of medical professionals to conquer it. As a one-year survivor of brain cancer, I have great hopes.”

New Strategies in the Search for a Brain Cancer Cure

Over the past five years the Ivy Center has established an international reputation for its expertise in the genetic analysis of individual tumors. At the Ivy Center, a genetic profile is created of every patient’s tumor with the goal to identify each tumor’s individual weaknesses and to develop new, personalized treatment strategies that target these weaknesses.

The Ivy Center’s genomic database — now one of the largest brain tumor research projects in the country — was developed in collaboration with the world-renowned Institute for Systems Biology. This collaboration brings together physicians and scientists in the fields of neurosurgery, neuropathology, systems biology, genomics and biostatistical analysis. Together they are determining how networks of genes and proteins interact in brain cancer to discover new targets for diagnostic tests and treatments.

In another partnership, the Ivy Center and the Allen Institute for Brain Science are creating a 3-D map of gene activity within brain tumors. These maps can then be compared with maps of gene activity in normal brain tissue to identify which genes are malfunctioning in the cancer tissue. Once these genes are identified the goal is to develop diagnostics and treatments that target these malfunctioning genes.

All data from these projects are being made available online to researchers around the world for free.

Clinical Trials for Brain Cancer Patients Brought to the Pacific Northwest

The Ivy Center’s expertise in the genetic analysis of brain tumors has led to its participation in a number of groundbreaking clinical trials:

Toca 511 Trial: The Ivy Center team is one of only eight sites in the country participating in the Toca trial. In this trial, a genetically engineered virus is used to insert a gene into glioblastoma cells. The gene produces a protein that activates a chemotherapy drug. Because the virus only inserts the gene into cancerous cells, the drug will only harm tumor cells. This approach allows high doses of the lethal drug to accumulate in the tumor cells, while sparing healthy cells nearby.
Temozolomide Trial: In this trial the Ivy Center team is leading a trial with the Seattle biotechnology company Accium Biosciences. In the study, researchers use Accium’s 15-ton particle accelerator to analyze tumor tissue to determine precisely just how much of the chemotherapy drug temozolomide reaches its target. This information will help determine which patients are most likely to benefit from the drug and which patients should try a different treatment. By using this new approach, it is hoped doctors will be able to better optimize brain cancer therapy so that they deliver the right drug to the right patient at the right dose.
DCVax Brain Cancer Vaccine Trial: In this groundbreaking study, a cancer vaccine is being used to train patients’ immune systems to attack and kill their brain cancer cells. Once trained, it is hoped these immune cells will track down and destroy any brain cancer cells that remain after surgery and to be ready to fight off any new tumor cells should the cancer recur.
Building a Community for Care and a Cure

Finally, since its founding the Ivy Center has made community involvement a high priority. The center’s community outreach efforts range from involving as many patients as possible in research to develop new treatments, to building community support for patients and their families to help them cope with the disease, to enlisting the community in fundraising and education efforts.

The Ivy Center was established with a lead gift from Ben & Catherine Ivy, and $11 million in philanthropic funds have been raised in support of the Center thus far. As a nonprofit, the Ivy Center depends heavily on community support to fund new research initiatives and patient participation in clinical trials, which is often not covered by insurance.

“We are never going to find more effective treatments for brain cancer without the help of the community,” said Dr. Foltz.

A highlight of these efforts is the Seattle Brain Cancer Walk, which has become a popular annual event that now draws thousands of participants and has raised more than $1.8 million for brain cancer research, care and advocacy.

Proceeds from Seattle’s Brain Cancer Walk have supported the Pacific Northwest region’s most promising brain cancer research projects as well as programs and services that benefit brain cancer patients, including clinical trials, advocacy programs, as well as comprehensive patient care and support services in the Pacific Northwest.

Over the past five years, the Ivy Center’s team of health providers and researchers has made real progress in understanding brain cancer and its treatment, said Dr. Foltz. “I am very hopeful that in the near term — we’re not talking decades — but in the next three to five years that we will see new therapies that will significantly help these patients,” Dr. Foltz said.

About Swedish

Swedish has grown over the last 103 years to become the largest non-profit health provider in the Greater Seattle area with 11,000 employees, more than 2,000 physicians and 1,700 volunteers. It is comprised of five hospital campuses (First Hill, Cherry Hill, Ballard, Edmonds and Issaquah); ambulatory care centers in Redmond and Mill Creek; and Swedish Medical Group, a network of more than 100 primary-care and specialty clinics located throughout the Greater Puget Sound area. In addition to general medical and surgical care including robotic-assisted surgery, Swedish is known as a regional referral center, providing specialized treatment in areas such as cardiovascular care, cancer care, neuroscience, orthopedics, high-risk obstetrics, pediatric specialties, organ transplantation and clinical research. For more information, visit,,, or

Swedish is affiliated with Providence Health & Services, which is a Catholic, not-for-profit organization founded by the Sisters of Providence in 1856 with 27 hospitals, 214 physician clinics and almost 53,000 employees across five states. Based in Renton, Wash., Providence Health & Services provides strategic and management services to integrated health-care systems in Alaska, California, Montana, Oregon and Washington state. For more information, visit


SOURCE Swedish Neuroscience Institute

Read more here:


Genentech: Adding Avastin to Radiation and Chemotherapy Extends Time People with Certain Brain Cancer Live without Disease Worsening


Genentech, a member of the Roche Group, announced that the Phase III AVAglio study of Avastin (bevacizumab) plus radiation and temozolomide chemotherapy in people with newly diagnosed glioblastoma met its co-primary endpoint of a significant improvement in progression-free survival (PFS).G

In the study, Avastin in combination with radiation and temozolomide chemotherapy significantly extended the time people with this aggressive form of primary brain cancer lived without their disease getting worse (PFS), compared to those treated with radiation and temozolomide chemotherapy plus placebo. The Company said data for final overall survival (OS), the other co-primary endpoint, are expected in 2013.

No new safety findings were observed in the AVAglio study, and adverse events were consistent with those seen in previous trials of Avastin across tumor types for approved indications. Full data from the AVAglio study will be submitted for presentation at an upcoming medical meeting.

Avastin is currently approved in the United States for the treatment of adults with glioblastoma who have progressive disease following prior therapy. In glioblastoma, it is approved for use as a single therapy and not in combination with other therapies. The effectiveness of Avastin is based on improvement in objective response rate. Currently, no data are available from randomized controlled trials demonstrating improvement in disease related symptoms or increased survival with Avastin in glioblastoma. The approval was granted under the U.S. Food and Drug Administration’s (FDA) accelerated approval program.

“This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy,” said Hal Barron, M.D., chief medical officer and head, Global Product Development.

Roche and Genentech plan to discuss these Phase III results with global regulatory authorities, including the European Medicines Agency (EMA) and FDA.

Genentech is a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions.

More information:

Grants for Brain Cancer Research Gain National Spotlight

Catherine Ivy put her commitment for furthering brain cancer research into action recently by awarding $10 million in grants to the Translational Genomics Research Institute (TGen). Her grant has gained both national and local attention:

It was recently featured in Scottsdale Business +Life and Chronicles of Philanthropy. Her hope is that by funding trailblazing research those diagnosed with brain cancer will double their life expectancy from 18 to 36 months over the next seven years.

Catherine Ivy Interviewed on “The Morning Scramble” on AZTV



Catherine Ivy was a special guest on “The Morning Scramble,” on AZTV in Phoenix, where she related the loss of her husband Ben to brain cancer and how this inspired the creation of The Ben and Catherine Ivy Foundation in the hope of finding a cure through brain cancer research.